For intimate life,
at its full potential

Request the clinical summary
Request a sample

Key Functional Benefits

AktiveX™ is a water-soluble, standardised hydroalcoholic botanical extract, studied in a 9-week randomised, double-blind, placebo-controlled trial of 100 men and women at just 150 mg a day. One active for both formulation lines.

  • Botanical: [to confirm] Extract type: standardised hydroalcoholic
  • extract Standardised for: [to confirm] Solubility: water-soluble
  • Studied dose: 150 mg a day Oral bioavailability:
  • 85.13% Suitable for: men and women IP: patent pending
AKTIVE-X™ · RESEARCH OVERVIEW

Understanding the Evidence

An organised overview of the reported study design, outcome measures and findings in men and women.

06 THE
EVIDENCE
STUDY AT A GLANCE
01 / PARTICIPANTS 100

Adults, men and women

02 / STUDY DESIGN Double-blind

Randomised, placebo-controlled*

03 / DURATION 9 weeks

As reported in supplied material

04 / DAILY DOSE 150 mg

Verify against the original study

01
REPORTED OUTCOMES

Men's Health

Hormonal measures, sexual-function scores and semen parameters.

HORMONAL MEASURE M01
79%

Testosterone

Reported increase in testosterone levels.

Original result requires verification
SEXUAL FUNCTION M02
136%

Sexual Desire Inventory

Reported increase in SDI score.

Confirm scale and calculation
SEXUAL FUNCTION M03
61%

Sexual Arousal Scale

Reported increase in SAS score.

Confirm scale and calculation
SEXUAL FUNCTION M04
51%

Erectile Function

Reported improvement in IIEF score.

Confirm outcome definition
ADDITIONAL MEASURES

Semen Parameters

Reported changes in the supplied study summary.

125%Sperm concentration
167%Sperm count per ejaculate
355%Active motile sperm
48%Immotile sperm reduction
02
REPORTED OUTCOMES

Women's Health

Sexual-function scores and reported hormonal measures.

PRIMARY QUESTIONNAIRE 70%

Female Sexual Function Index

Reported improvement in FSFI score, according to the supplied reference material.

Verify the score calculation, participant group and source before publication.
SEXUAL DESIRE INVENTORY

Reported SDI score increase

175%
SEXUAL AROUSAL SCALE

Reported SAS score increase

72%
HORMONAL MEASURES

Reported Changes

FSH 270% Reported increase
LH 356% Reported increase
Prolactin 23% Reported reduction

Hormonal outcomes require careful clinical interpretation. Confirm all figures and laboratory methods against the original report.

BEYOND THE NUMBERS

Methods & Supporting Evidence

Important context for interpreting the reported results.

01 Understanding the FSFI questionnaire +
The Female Sexual Function Index is a validated questionnaire covering desire, arousal, lubrication, orgasm, satisfaction and pain. The study's specific version, scoring method and interpretation should be confirmed.
02 Pharmacokinetic information +
The supplied material reports 85.13% oral bioavailability, a 15-minute onset and plasma presence of up to 6 hours. These figures require confirmation from the relevant pharmacokinetic study. Plasma presence does not itself demonstrate a clinical benefit.
03 Safety and tolerability +
The source material refers to NOAEL and a lack of reported adverse findings. The underlying safety report, tested dose, duration and adverse-event data should be reviewed. A short study cannot establish that a product is universally safe.
04 Published study and references +
Study citation: Add the full author list, study title, journal, publication year, volume, pages and DOI or permanent URL. If the figures come from a product brochure rather than a peer-reviewed publication, identify that source accurately.
i
Important information

Percentages shown are transcribed from the supplied reference material and have not been independently verified. Reported study findings do not guarantee individual results. Confirm the underlying evidence before publication. This content is informational and does not replace professional medical advice.

Enquire

Reach out to the experts
at K Patel Phyto.

Contact us today for clinical study highlights and formulation support.

Name
Please indicate any Ingredient related Enquiry
Have you had a facial before?
Have you had a reaction?
Creams, peels, serums

Certifications

Proud Members of

Science that changes lives.
Deliverd to your inbox

Why AktiveX?

Everything we develop starts with on question: what does
this make possible in a person’s life? The answer drives every
compound, every batch, every partnership.

Low-Dose

Studied at 150 mg a day, leaving room in small formats.

Water-soluble

Works in gummies, chocolates, gels and oral dissolving films.

For men and women

One active for both formulation lines.

Studied in 100 adults

Randomised, double-blind, placebo-controlled, 9 weeks.

RESEARCH & CLINICAL EVIDENCE

6. The Evidence

A structured overview of the study details, reported outcomes in men and women, and supporting research information.

STUDY POPULATION 100 Adults Men and women
STUDY DESIGN Randomised Double-blind, placebo-controlled
STUDY DURATION 9 Weeks As stated in the supplied summary
RESEARCH SUMMARY

Study Findings at a Glance

Evidence Review
FIELD STUDY DETAILS REVIEW NOTES
Study Design Randomised, double-blind, placebo-controlled study. The supplied summary describes 100 adults, including men and women, receiving 150 mg per day over 9 weeks. ◆ Verify the product identity, dose, study protocol, participant demographics and duration against the original publication.
01 Men's Outcomes
Hormonal & Sexual Function
79% Reported increase in testosterone
136% Reported increase in Sexual Desire Inventory (SDI) score
61% Reported increase in Sexual Arousal Scale (SAS) score
51% Reported improvement in International Index of Erectile Function (IIEF) score
Confirm every percentage against the original report. Distinguish relative changes from absolute changes and clarify baseline values.
Semen Parameters
125% Reported increase in sperm concentration
167% Reported increase in sperm count per ejaculate
355% Reported increase in active motile sperm
48% Reported reduction in immotile sperm
Confirm the figures, units, definitions of motility and whether changes were statistically significant.
02 Women's Outcomes
Sexual Function
70% Reported improvement in Female Sexual Function Index (FSFI) score
175% Reported increase in Sexual Desire Inventory (SDI) score
72% Reported increase in Sexual Arousal Scale (SAS) score
Confirm the percentages, scoring methods, outcome definitions and population studied.
Hormone Balance
270% Reported increase in follicle-stimulating hormone (FSH)
356% Reported increase in luteinising hormone (LH)
23% Reported reduction in prolactin
◆ Hormonal findings require careful interpretation. Confirm laboratory data and clinical context before making health-related claims.
03 Measurement & Supporting Information
FSFI Explained The Female Sexual Function Index (FSFI) is a validated questionnaire assessing domains such as desire, arousal, lubrication, orgasm, satisfaction and pain. Specify the questionnaire version, scoring approach and how the reported percentage was calculated.
Pharmacokinetics
Reported oral bioavailability 85.13%
Reported onset of action 15 minutes
Reported plasma presence Up to 6 hours
Verify the pharmacokinetic study, formulation, methodology and meaning of each measurement. Do not equate plasma presence with clinical effect.
Safety The supplied material refers to a No Observed Adverse Effect Level (NOAEL) and reports no adverse findings in the study summary. Do not use absolute claims such as “100% safe.” Verify the safety evidence, adverse-event records and whether the cited NOAEL applies to this specific formulation and dose.
Citation Published Research Reference

[Insert authors, full study title, journal, publication year, volume, pages and DOI or URL.]

Add the original publication or clearly state when supporting data are available only from product materials.
i
About these findings

Figures shown here are transcribed from the supplied reference material and have not been independently verified. Results from an individual study do not establish that the same effects will occur in every person. Consult the original research and an appropriately qualified healthcare professional when interpreting clinical findings.

Formats

Capsules

Beverages

Capsules

Chocolates

Tablets

Gels

Gummies

Oral dissolving films

Powders and sachets

Applications

Dietary Suppliments

Functional food and beverage

Sports nutrition

150 mg a day, as studied.

Enquire

Reach out to the experts
at K Patel Phyto.

Contact us today for clinical study highlights and formulation support.

Certifications

Proud Members of

Science that changes lives.
Deliverd to your inbox

Developing with AktiveX™?

Our technical team will share the clinical summary and formulation guidance for your market.

Request the clinical summary
Request a sample
Scroll to Top